TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00872144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sativex
Description: Sativex (or placebo) will be dispensed identical 5.5 ml containers. Participants will be instructed to start with a dose of 1 spray trans-mucosally at 1800 hrs. If there are no limiting adverse effects such as sedation or dizziness, participants will be instructed to increase the dose to 2 sprays- one in the morning and the other in the early evening on day two. Participants may increase the dose by 1-2 sprays per day to a maximum dose of 12 sprays per day given 3 sprays 4 times per day. In the initial titration phase participants will be instructed to space each dose actuation 15 minutes apart until accustomed to the preparation. Participants will titrate the dose to a level where they obtain an analgesic effect without limiting side effects.
Study: NCT03807310

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Targeted nutrient supplementation (Long-drink)
Description: Once daily for at least 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Once daily for at least 12 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counselling
Description: Counselling on healthy lifestyle (in particular physical activity, smoking cessation) and weight management by motivational interviewing
Study: NCT02323659

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate 20mg per dose, administered orally, once every week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon Alfa-2b
Description: Interferon Alfa-2b 3 million international units (MIU), administered 3 times per week
Study: NCT05139966

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mouthwash Product
Description: The participants were requested to rinse 10 ml of the mouthwash 2 times / day (morning and evening) for 1 min after toothbrushing (a non-F dentifrice was used throughout the study).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mouthwash Product
Description: The participants were requested to rinse 10 ml of the mouthwash 2 times / day (morning and evening) for 1 min after toothbrushing (a non-F dentifrice was used throughout the study).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mouthwash Product
Description: The participants were requested to rinse 10 ml of the mouthwash 2 times / day (morning and evening) for 1 min after toothbrushing (a non-F dentifrice was used throughout the study).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mouthwash Product
Description: The participants were requested to rinse 10 ml of the mouthwash 2 times / day (morning and evening) for 1 min after toothbrushing (a non-F dentifrice was used throughout the study).
Study: NCT00276874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole; 0-30 mg; oral; daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo; 0 mg; oral; daily
Study: NCT02081170

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous platelet concentrate
Description: 1. pars plana vitrectomy~2. internal limiting membrane removal~3. Fluid-air exchange~4. Intravitreal autologous platelet concentrate injection~5. Intravitreal gas (14% C3F8) injection~6. Keep prone position for 7-14 days after surgery
Study: NCT04134975

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spine surgery
Description: surgery with pedicle screw placement between L1 and S1

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spine surgery
Description: surgery with pedicle screw placement between L1 and S1
Study: NCT00669149

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bivalirudin + clopidogrel + aspirin
Study: NCT04554316

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Steri-strip
Description: Steri-Strips (3M Health Care, St. Paul, Minn) are a commonly used means of covering surgical incisions following many operations. Use of adhesive surgical tape over incisions maintains epidermal approximation in primary skin closure while limiting exposure to the environment, theoretically improving cosmesis and limiting risk of infection.
Study: NCT04576793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-ER176
Description: 11C-ER176 sticks to parts of the brain where there is inflammation. Past studies have shown that inflammation is present in the brains of patients with Alzheimer's disease. The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease. 11C-ER176 will be administered at activity up to 20 millicurie (mCi) per injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 11C-ER176
Description: 11C-ER176 sticks to parts of the brain where there is inflammation. Past studies have shown that inflammation is present in the brains of patients with Alzheimer's disease. The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease. 11C-ER176 will be administered at activity up to 20 millicurie (mCi) per injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-MK6240
Description: MK-6240 measures a protein called in the brain. MK-6240 is experimental but has been used in several human studies before and has been proven to accurately measure tau in the brain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F-MK6240
Description: MK-6240 measures a protein called in the brain. MK-6240 is experimental but has been used in several human studies before and has been proven to accurately measure tau in the brain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Florbetaben
Description: Florbetaben has been approved by the FDA to help diagnose Alzheimer's disease. florbetaben measures amyloid in the brain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F-Florbetaben
Description: Florbetaben has been approved by the FDA to help diagnose Alzheimer's disease. florbetaben measures amyloid in the brain.
Study: NCT03807310

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Counselling
Description: Counselling on healthy lifestyle (in particular physical activity, smoking cessation) and weight management by motivational interviewing
Study: NCT01945840

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux en Y Gastric Bypass Surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gut hormone infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Very low calorie diet
Study: NCT04576793

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Inflammation can also be measured by looking at certain proteins in the spinal fluid. In order to measure these proteins in the spinal fluid, the investigators will perform a lumbar puncture (spinal tap).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Puncture
Description: Inflammation can also be measured by looking at certain proteins in the spinal fluid. In order to measure these proteins in the spinal fluid, the investigators will perform a lumbar puncture (spinal tap).
Study: NCT03506009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban combined with rt-PA
Description: Argatroban as a 100-ug/kg bolus over 3 to 5 minutes was administered intravenously within 1 hour of the tPA bolus followed by a continuous Argatroban infusion of 1.0 ug/kg per minute for 48 hours adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rt-PA
Description: Intravenous throbolysis with 0.9mg/kg rtPA.
Study: NCT01904383

Intervention type: DRUG
Intervention: Trazenta
Description: 1 tablet of 5 mg Trazenta tablets once daily
Study: NCT05233553

Intervention type: OTHER
Intervention: control of liver enzymes
Description: follow-up with clinical and laboratory measurements
Study: NCT02102581

Intervention type: PROCEDURE
Intervention: short time tourniquet
Description: short time tourniquet: the tourniquet starting from the implantation of prosthesis to the completion of the operation.
Study: NCT01097161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: speech therapy with the assistance of an acoustical analysis program
Description: Two weekly speech sessions realized on individual basis for three months period
Study: NCT02768740

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone hemisuccinate
Description: In the 200-mg group, patients received an intravenous bolus of 50 mg of hydrocortisone every six hours for seven days associated with a continuous infusion of placebo for five days. In the 300-mg group, patients received an initial bolus of 100 mg of hydrocortisone followed by a continuous infusion of 300 mg per day for five days associated with a bolus of placebo every six hours for seven days.
Study: NCT02894372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral spray 1
Description: Research participants got topical oral spray immediately after surgery (hospital patients) and from the first doctor visit with pharyngeal disease (clinic outpatients).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral spray 2
Description: Research participants got topical oral spray immediately after surgery (hospital patients) and from the first doctor visit with pharyngeal disease (clinic outpatients).
Study: NCT02768740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone hemisuccinate
Description: In the 200-mg group, patients received an intravenous bolus of 50 mg of hydrocortisone every six hours for seven days associated with a continuous infusion of placebo for five days. In the 300-mg group, patients received an initial bolus of 100 mg of hydrocortisone followed by a continuous infusion of 300 mg per day for five days associated with a bolus of placebo every six hours for seven days.
Study: NCT03832998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab Dose 1
Description: Participants in the low body-weight group at day 1 and who are randomized to Dose Level 1 will receive this dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab Dose 2
Description: Participants in the low body-weight group at day 1 who are randomized to Dose Level 2 and participants in the high body-weight group at day 1 who are randomized to Dose Level 1 will receive this dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab Dose 2
Description: Participants in the low body-weight group at day 1 who are randomized to Dose Level 2 and participants in the high body-weight group at day 1 who are randomized to Dose Level 1 will receive this dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab Dose 3
Description: Participants in the high body-weight group at day 1 who are randomized to Dose Level 2 will receive this dose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching dose for erenumab dose 1, 2 and 3.
Study: NCT01508585

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Based Cognitive Behavioral Therapy
Description: 6 sessions of Cognitive Behavioral Therapy (CBT), lasting approximately 60 minutes each.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Based Cognitive Behavioral Therapy
Description: 6 sessions of Cognitive Behavioral Therapy (CBT), lasting approximately 60 minutes each.
Study: NCT03108079

Intervention type: DEVICE
Group type: OTHER
Intervention: Cystosure Urinary Access System
Description: 1. Demonstrate the 3D bladder wall anatomy with 300 cc of fluid infused with each of the following bladder drainage mechanisms~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)~2. Compare the fluid flow pattern during bladder drainage for~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)~3. Compare the 3D bladder wall anatomy after emptying the bladder with~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)

Intervention type: DEVICE
Group type: OTHER
Intervention: Foley Catheter
Description: 1. Demonstrate the 3D bladder wall anatomy with 300 cc of fluid infused with each of the following bladder drainage mechanisms~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)~2. Compare the fluid flow pattern during bladder drainage for~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)~3. Compare the 3D bladder wall anatomy after emptying the bladder with~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)
Study: NCT00252187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B-type Natriuretic Peptide (BNP)
Description: BNP hormone self-administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo self-administered subcutaneously twice daily for 8 weeks.
Study: NCT04160078

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) Intervention
Description: * 1-hour session on sleep hygiene and 7-week follow up using a mindfulness app, an app that features guided meditation and can be used to assess adherence.~* Sleep log diary: self report of sleep records~* Wrist Actigraphy, to monitor sleep patterns. Participants will be instructed on wearing the sleep monitor (Spectrum, Philips Respironics, Murrysville, PA) on their non-dominant wrist for the next 7-weeks
Study: NCT00440154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE5530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE5530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE5530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE5530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE5530

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ezetimibe
Study: NCT00526773

Intervention type: OTHER
Group type: OTHER
Intervention: telephone management plus a motivational intervention
Description: heart failure intervention

Intervention type: OTHER
Group type: OTHER
Intervention: telephone management with standard patient education
Description: heart failure intervention
Study: NCT02330679

Intervention type: DRUG
Group type: OTHER
Intervention: Desvenlafaxine
Description: The intervention will consist of a 2-week single-blind placebo run-in phase followed by a 12-week open-label trial with desvenlafaxine (a SNRI medication)

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Study: NCT02181257

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Extracorporeal Photopheresis (ECP)
Description: Procedure:~ECP treatments will be performed using one of two Therakos systems. Both systems use the drug Methoxsalen

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Extracorporeal Photopheresis (ECP)
Description: Procedure:~ECP treatments will be performed using one of two Therakos systems. Both systems use the drug Methoxsalen

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention in the SOC / Retrospective Chart review.
Description: SOC Retrospective chart review similar to a control group
Study: NCT03873779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ZELTIQ System
Description: The CoolSculpting machine will be used to perform the treatments.
Study: NCT04368585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)
Description: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)
Description: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)
Description: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL)
Description: 20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL) oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 40 mg (1 x 40 mg capsule) omeprazole administered QD
Study: NCT03560622

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: multi-modality neuroimaging
Description: multi-modality neuroimaging consists of structural imaging, diffusion tensor imaging (DTI), task-based functional MRI (t-fMRI), and resting state functional MRI (rs-fMRI).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: multi-modality neuroimaging
Description: multi-modality neuroimaging consists of structural imaging, diffusion tensor imaging (DTI), task-based functional MRI (t-fMRI), and resting state functional MRI (rs-fMRI).
Study: NCT01492257

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared Decision Making Intervention
Description: Digital video discs and booklets produced by the Foundation for Informed Medical Decision Making and Health Dialog; a question-prompting phone call with a trained health coach; audio-recordings of the patient-surgeon consultation; and a copy of the surgeon's dictated note.
Study: NCT01020305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Temsirolimus is an inhibitor of the mammalian target of rapamycin (MTOR, aka HGNC:3942)~IUPAC name: (1R,2R,4S)-4-{(2R)-2-\[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido\[2,1-c\]\[1,4\]oxazacyclohentriacontin-3-yl\]propyl}-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casodex (bicalutamide)
Description: Casodex (bicalutamide) 50 mg/day PO
Study: NCT04520035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab
Description: Carilizumab 200 mg, every 3 weeks, 2 cycles.Paclitaxel 175 mg / m2, D1, every 3 weeks, 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Cisplatin 75mg / m2 D1, conventional hydration for 3 days, every 3 weeks, 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemotherapy
Description: Neoadjuvant Chemotherapy
Study: NCT02058810

Intervention type: DEVICE
Group type: OTHER
Intervention: Nasal high flow

Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional nasal oxygen
Study: NCT04656522

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participatory Comic Intervention
Description: This participatory comic intervention promotes sexual violence prevention and post-rape care with refugee youth and health care providers. In 4-hour workshops, a customized comic book featuring eight sexual violence scenarios will be distributed. Each 1-page scenario speaks to a unique theme of sexual violence experiences among youth or post-rape care preferences. During the workshop participants will explore social, sexual, and psychological needs of youth in Bidi Bidi and practice ways of developing and maintaining healthy relationships (youth) as well as discuss post-rape care responses that attend to the needs and priorities of young refugees in Bidi Bidi who have experienced sexual violence (health care providers). Each workshop will include 20 participants and will be facilitated by trained staff from Real Medicine, Uganda. Further, each workshop will have at least 2 facilitators who are trained in the bystander model.
Study: NCT01563471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: Subjects will be randomised to one of four treatment sequences. Subjects will receive single bolus i.v. injection of 40, 80 or 160 mcg/kg body weight of trial drug or placebo on each day of the three separate visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: Subjects will be randomised to one of four treatment sequences. Subjects will receive single bolus i.v. injection of 40, 80 or 160 mcg/kg body weight of trial drug or placebo on each day of the three separate visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: Subjects will be randomised to one of four treatment sequences. Subjects will receive single bolus i.v. injection of 40, 80 or 160 mcg/kg body weight of trial drug or placebo on each day of the three separate visits

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: activated recombinant human factor VII
Description: Subjects will be randomised to one of four treatment sequences. Subjects will receive single bolus i.v. injection of 40, 80 or 160 mcg/kg body weight of trial drug or placebo on each day of the three separate visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subjects will be randomised to one of four treatment sequences. Subjects will receive single bolus i.v. injection of 40, 80 or 160 mcg/kg body weight of trial drug or placebo on each day of the three separate visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subjects will be randomised to one of four treatment sequences. Subjects will receive single bolus i.v. injection of 40, 80 or 160 mcg/kg body weight of trial drug or placebo on each day of the three separate visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subjects will be randomised to one of four treatment sequences. Subjects will receive single bolus i.v. injection of 40, 80 or 160 mcg/kg body weight of trial drug or placebo on each day of the three separate visits

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will be randomised to one of four treatment sequences. Subjects will receive single bolus i.v. injection of 40, 80 or 160 mcg/kg body weight of trial drug or placebo on each day of the three separate visits
Study: NCT02408406

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Intervention
Description: Use PatientCareAnywhere system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Use PatientCareAnywhere system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Use PatientCareAnywhere system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies